Etanercept: A clinical review of current and emerging indications

Shikha Nanda; Joan M. Bathon

doi:10.1517/14656566.5.5.1175

Etanercept: A clinical review of current and emerging indications

Shikha Nanda, Joan M. Bathon

School of Medicine

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

The recent development of inhibitors of TNF-α has provided the opportunity for a more targeted and highly effective approach to the treatment of chronic inflammatory illnesses such as rheumatoid arthritis. Since the initial approval of etanercept as a treatment for rheumatoid arthritis, additional indications, including psoriatic arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis, have also received FDA approval. More than 220,000 patients have been treated with etanercept so far. This review summarises the body of knowledge accumulated so far on etanercept (Enbrel®) since it entered the market 5 years ago. 2004

Original language	English (US)
Pages (from-to)	1175-1186
Number of pages	12
Journal	Expert Opinion on Pharmacotherapy
Volume	5
Issue number	5
DOIs	https://doi.org/10.1517/14656566.5.5.1175
State	Published - May 2004

Keywords

Etanercept
Rheumatoid arthritis
Tumour necrosis factor

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1517/14656566.5.5.1175

Cite this

@article{7b7dd0d495254c62aa885a4a3d18d61a,

title = "Etanercept: A clinical review of current and emerging indications",

abstract = "The recent development of inhibitors of TNF-α has provided the opportunity for a more targeted and highly effective approach to the treatment of chronic inflammatory illnesses such as rheumatoid arthritis. Since the initial approval of etanercept as a treatment for rheumatoid arthritis, additional indications, including psoriatic arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis, have also received FDA approval. More than 220,000 patients have been treated with etanercept so far. This review summarises the body of knowledge accumulated so far on etanercept (Enbrel{\textregistered}) since it entered the market 5 years ago. 2004",

keywords = "Etanercept, Rheumatoid arthritis, Tumour necrosis factor",

author = "Shikha Nanda and Bathon, {Joan M.}",

year = "2004",

month = may,

doi = "10.1517/14656566.5.5.1175",

language = "English (US)",

volume = "5",

pages = "1175--1186",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Etanercept

T2 - A clinical review of current and emerging indications

AU - Nanda, Shikha

AU - Bathon, Joan M.

PY - 2004/5

Y1 - 2004/5

N2 - The recent development of inhibitors of TNF-α has provided the opportunity for a more targeted and highly effective approach to the treatment of chronic inflammatory illnesses such as rheumatoid arthritis. Since the initial approval of etanercept as a treatment for rheumatoid arthritis, additional indications, including psoriatic arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis, have also received FDA approval. More than 220,000 patients have been treated with etanercept so far. This review summarises the body of knowledge accumulated so far on etanercept (Enbrel®) since it entered the market 5 years ago. 2004

AB - The recent development of inhibitors of TNF-α has provided the opportunity for a more targeted and highly effective approach to the treatment of chronic inflammatory illnesses such as rheumatoid arthritis. Since the initial approval of etanercept as a treatment for rheumatoid arthritis, additional indications, including psoriatic arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis, have also received FDA approval. More than 220,000 patients have been treated with etanercept so far. This review summarises the body of knowledge accumulated so far on etanercept (Enbrel®) since it entered the market 5 years ago. 2004

KW - Etanercept

KW - Rheumatoid arthritis

KW - Tumour necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=2542552847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542552847&partnerID=8YFLogxK

U2 - 10.1517/14656566.5.5.1175

DO - 10.1517/14656566.5.5.1175

M3 - Article

C2 - 15155116

AN - SCOPUS:2542552847

SN - 1465-6566

VL - 5

SP - 1175

EP - 1186

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 5

ER -

Etanercept: A clinical review of current and emerging indications

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this